Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use.

Acta Derm Venereol · 2021 · PMC9413654 · PMID 34043020

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

In conclusion, this subgroup analysis showed that, in adolescent patients with moderate-to-severe AD, irrespective of prior SIS use, dupilumab treatment compared with placebo resulted in higher and nominally significant treatment effects across multiple efficacy endpoints.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.